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Summary
BACKGROUND: The majority of germ cell tumour (GCT)
patients can be cured by orchiectomy followed by active
surveillance or subsequent systemic and/or local treat-
ments. There are various guidelines for a structured fol-
low-up including radiographic and clinical examinations.
OBJECTIVE: The Swiss Austrian German Testicular Can-
cer Cohort Study (SAG TCCS) prospectively evaluates fol-
low-up, indicator of relapse and late toxicities. This is a de-
scriptive analysis; we present baseline characteristics and
treatment strategies for the first 299 patients with primary
GCT or relapsed GCT after completion of treatment.
RESULTS: Of the patients included in this study, 192
(64.2%) had seminoma and 107 (35.8%) non-seminoma
tumour. Mean age was 41 years (standard deviation [SD]
11.7) for seminoma and 31 (SD 9.3) years for non-semino-
ma patients. Median tumour size was 3.5 cm (interquartile
range 0–12) in both histological groups. Among semino-
ma patients, 81 (42.2%) had primary tumours >4cm; 154
(80.2%) seminoma patients had stage I, 26 (13.5%) stage
II and 12 (6.3%) stage III disease. Fifty-seven (53.3%)
non-seminoma tumours were stage I, 29 (27.1%) stage
II and 21(19.6%) stage III. Marker-positive disease was
present in 58 (30.2%) seminoma patients and 78 (72.9%)
non-seminoma patients. Of 154 stage I seminoma pa-
tients, 89 (57.8%) chose active surveillance and 65
(42.2%) adjuvant chemotherapy. Twenty-six (45.6%)
stage I non-seminoma patients had high-risk disease; 23
of these were treated with adjuvant chemotherapy and 3
chose active surveillance. Among the 30 (52.6%) low risk
stage I patients, all opted for active surveillance. Twelve
(46.2%) stage II seminoma patients had radiotherapy, 14
(53.8%) were treated with three to four cycles of
chemotherapy. All stage III seminoma patients, and all
stage II and III non-seminoma patients were treated with
three to four cycles of chemotherapy. Treatment decisions
were made at the respective centre. Five patients did not
receive therapy that conformed with guidelines.
CONCLUSION: It is important to enrol GCT patients in
prospective studies in general, but also in follow-up stud-
ies to assess baseline characteristics, oncological out-
come, and long-term toxicity and to validate the perfor-
mance of follow-up schedules. This is the first time that
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the distribution of disease, detailed baseline characteris-
tics and the respective treatment of men with GCT is col-
lected in a prospective manner in German speaking coun-
tries (Switzerland, Austria and Germany) and therefore
patterns of care have been evaluated. SAG TCCS results
will inform on future modifications of surveillance sched-
ules and follow-up procedures.
: Trial registration number: NCT02229916 (Clinicaltri-
als.gov)
Keywords: seminoma, non-seminoma, active surveil-
lance, follow-up, late toxicity, secondary malignancy, sex-
ual health
Introduction
Germ cell tumours (GCTs) are rare malignancies, but are
the most common solid tumours among men between the
ages of 15 and 40 years [1]. Throughout the late 20th cen-
tury, the increase in incidence has been greatest in men of
European descent [2]. About 400 men are diagnosed with
GCTs in Switzerland every year [3]. Histologically, GCTs
comprises pure seminomas in approximately 60% of pa-
tients and other tumour types in 40% [2]. The majority of
GCT patients can be cured by orchiectomy and, if neces-
sary, subsequent local or systemic treatments [4]. Active
surveillance is a widely accepted strategy in stage I GCT
and incorporates close follow-up, with chemotherapy giv-
en only to patients subsequently relapsing, thus avoiding
treatment in about 50 to 90% of patients [5, 6]. Alterna-
tively, adjuvant chemotherapy can be administered, espe-
cially when high-risk features are present, and this min-
imises the risk of recurrence to below 5% [7–9]. Overall
survival for stage I GCT is close to 100% regardless of the
management chosen [6]. In stage IIA and selected stage
IIB seminoma radiotherapy is an option, whereas all oth-
er metastatic GCTs require cisplatin-based chemotherapy
[10]. These therapy strategies result in a 10-year overall
survival rate of above 95%. However, strict adherence to
treatment guidelines is a prerequisite [11, 12].
Given the excellent prognosis, long follow-up after initial
treatment is needed, focusing not only on relapse but also
on side effects and long-term toxicities including increased
risk of secondary malignancies and cardiovascular morbid-
ity, which can occur years after GCT treatment [13]. An in-
terdisciplinary Swiss working group developed evidence-
based recommendations for the follow-up of GCT patients
that were later adopted by the German Testicular Cancer
Study Group [5, 14–16].
Currently, no treatment and outcome data on GCT patients
are available for Switzerland. The National Institute for
Cancer Epidemiology and Registration (NICER) covers
only part of Switzerland and provides statistics only on in-
cidence and mortality. We believe that in GCT patients,
more extensive data collection and analysis is needed to
study outcome and late toxicities. In contrast to the United
Kingdom and Scandinavian countries, in Switzerland,
Austria or Germany the care of GCT patients is neither
standardised nor centralised. The Swiss Austrian German
Testicular Cancer Cohort Study (SAG TCCS) is the first
study to prospectively evaluate the initial indicators of re-
lapse in GCT patients after completion of curative treat-
ment, to measure the usefulness of the various follow-up
examinations and to collect data on late sequelae follow-
ing treatment, namely impairment of cardiovascular, renal,
pulmonary, gonadal, neuronal and cognitive function, psy-
chosocial disorders, sexual health and socioeconomic as-
pects.
SAG TCCS is in accordance with recommendations for fu-
ture research strategies in GCT published 2010 by Travis et
al. [13] These recommendations include: life-long follow-
up within the setting of a large prospective cohort study to
ascertain risks of emerging toxicities and the evolution of
known late sequelae; the development of comprehensive
risk prediction models; elucidation of the effect(s) of expo-
sure to platinum; assessment of the overall burden of med-
ical and psychosocial morbidity; and the development of
evidence-based guidelines for long-term follow-up and in-
terventions.
Here we report the baseline characteristics and the treat-
ment strategies for the first 299 patients enrolled in this co-
hort in Switzerland, Austria and Germany between Janu-
ary 2014 and July 2017, while prospective registration is
currently ongoing. Therapies were chosen at the discretion
of the local investigators based on their respective in-house
guidelines. We will report on initial indicators of relapse
and on late toxicities in a later manuscript.
Materials and methods
The SAG TCCS of consecutive newly diagnosed and re-
lapsed male GCT patients after completion of curative/
salvage treatment is a Swiss, German and Austrian mul-
ticentre prospective cohort study. In Switzerland, urolo-
gists and medical oncologists in private practice, and sec-
ondary and tertiary referral centres were made aware of
this cohort study with several mailings. In addition, all par-
ticipants at the Swiss Group for Clinical Cancer Research
Genitourinary Project Group semi-annual meetings were
approached. Participation is voluntary.
Male patients of any age can be included after giving writ-
ten informed consent if they have a histologically proven
seminoma or other GCT tumour type and are within 3
months of treatment completion (surgery of primary tu-
mour, adjuvant chemotherapy, chemotherapy, radiothera-
py, salvage therapy, resection of residual disease if applica-
ble). Exclusion criteria are pre-existent malignancy within
the past 5 years, with exception of previous GCT, and in-
ability for any reason to comply with the trial investiga-
tions of the follow-up schedules. Patients are classified in-
to one of nine follow-up schedules based on initial stage
and risk factors, as published by Cathomas et al. [5]
Data collection at study inclusion comprises patient base-
line characteristics, tumour assessments, treatment strate-
gies and tumour markers, and thereafter mode of relapse
detection and stage of disease at relapse. The database is
set to assess late toxicities, including secondary malignan-
cies, gathered prospectively at the standardised follow-up
visits and investigations for at least 10 years, or until loss
to follow-up or withdrawal of consent. Depending on fund-
ing and research interest, follow-up can be extended fur-
ther while the study is ongoing. Data are entered locally in
electronic case report forms and saved and analysed cen-
trally at the Institute of Social and Preventive Medicine
(ISPM) in Bern, Switzerland. The data collection is in ac-
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cordance with the Declaration of Helsinki and ethical ap-
proval was obtained.
The primary objective of the SAG TCC study will be to de-
termine the diagnostic performance and the clinical impact
of a variety of tests, including conventional radiographs,
computed tomography scans, abdominal ultrasound, serum
tumour markers including alpha-fetoprotein (AFP), human
chorionic gonadotropin (HCG) or lactate dehydrogenase
(LDH), and clinical signs and symptoms that aim at early
detection of relapse after curative therapy with document-
ed complete remission or partial remission.
Secondary objectives will be: to determine the rate and
time-point of relapse, and the rate of intermediate and
poor-prognosis disease at relapse; to compare patient char-
acteristics at baseline and at relapse; and to assess late tox-
icity, i.e., secondary neoplasms, cardiovascular risk factors
and disease, treatment sequelae due to organ dysfunction
following cancer treatment and, finally, sexual health and
socioeconomic wellbeing. These data will be published af-
ter a longer follow-up.
We used Fisher’s exact test for binary/categorical variables
and Wilcoxon rank-sum tests for continuous variables.
This is a descriptive analysis; we present baseline charac-
teristics and treatment strategies for the first 299 patients
within SAG TCCS.
Results
A total of 299 patients were included in 14 Swiss, 1 Aus-
trian, and 1 German centre between 10 January 2014 and
1 September 2017. The majority of patients (n = 276) are
from Switzerland. The 14 Swiss participating sites are all
secondary and tertiary oncology centres; two private urol-
ogy practices have so far not recruited patients. The Ger-
man and Austrian sites are tertiary oncology referral cen-
tres. Study recruitment status is summarised in figure 1.
Age, histology and tumour size
Mean age at inclusion was 40.9 (standard deviation [SD]
11.7) and 31.1 (SD 9.3) years in seminoma and non-semi-
noma patients, respectively. Of the 299 patients, 192
(64.2%) had seminoma and 107 (35.8%) another tumour
type.
Median primary tumour diameter was 3.5 cm in seminoma
and 3.5 cm in non-seminoma patients, with 81 (42.2%) of
the seminoma patients presenting with a primary tumour
≥4 cm. In stage I seminoma, primary tumour size was ≥4
cm in 62 (40.2%) patients. Rete testis invasion (RTI) was
found in 89 (46.4%) seminoma patients and 74 (48.1%)
patients with seminoma stage I. Lymphovascular invasion
(LVI+) was present in 56 (52.3%) non-seminoma patients
and 26 (45.6%) non-seminoma patients with stage I.
In SAG TCCS, there is no central pathology review and
data are taken from local pathology reports.
Tumour markers and stage of disease
Three serum tumour markers have established roles in the
management of men with GCT: alpha-fetoprotein (AFP),
human chorionic gonadotropin (HCG) and lactate dehy-
drogenase (LDH). Any marker elevation constitutes mark-
er-positive disease. Post-orchiectomy levels of tumour
markers are used in risk stratification.
In summary, 58 (30.2%) seminoma and 78 (72.9%) non-
seminoma patients had marker-positive disease, and 134
Figure 1: Distribution of GCT patientsAC = adjuvant chemotherapy; AS = active surveillance; BEP = bleomycin, etoposide, cisplatin; CT = cu-
rative chemotherapy; EP = etoposide, cisplatin; PCR = postchemotherapy resection; RT = radiotherapy; SAG TCCS = Swiss Austrian German
Testicular Cancer Cohort Study; VIP = etoposide, ifosfamide, cisplatin.
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(69.8%) seminoma and 29 (27.1%) non-seminoma patients
had marker-negative disease. All tumour markers (AFP,
HCG and LDH) were available for all patients before start
of treatment. In stage I and II seminoma, elevated tumour
markers were present in 26.0 and 34.6% of patients, re-
spectively; however, in stage III seminoma, 66.7% of pa-
tients had marker-positive disease.
Primary extragonadal GCT (retroperitoneal and mediasti-
nal) was present in eight patients, three with seminoma and
five with non-seminoma GCTs.
Twenty-five stage II seminoma and all 29 stage II non-
seminoma patients were classified as good prognosis ac-
cording to the International Germ Cell Cancer Collabo-
rative Group (IGCCCG) classification. One stage II
seminoma patient was classified as IGCCCG intermediate
prognosis.
In stage III seminoma, 9 (75.0%) patients were classified
as IGCCCG [17] good and 3 (25.0%) intermediate prog-
nosis. Of the stage III non-seminoma patients, 10 (47.6%)
were classified as IGCCCG good, 6 (28.6%) intermediate
and 5 (23.8%) poor prognosis.
Baseline characteristics are summarised in tables 1–3.
Treatment
The majority of stage I seminoma patients (n = 89, 57.8%)
chose active surveillance, and of these 42 (47.2%) present-
ed with neither a tumour size ≥4 cm nor RTI. However,
14 (15.7%) patients with a tumour diameter ≥4 cm and
RTI opted for active surveillance. Adjuvant treatment with
one cycle of carboplatin AUC7 (i.e., the dosage reaching
an area under the curve of 7 mg/ml/min) was given to 61
(39.6%) stage I seminoma patients. Three (1.9%) patients
were treated with two cycles of carboplatin AUC7 and one
patient (0.6%) with carboplatin AUC7 and radiotherapy.
The majority of patients who received adjuvant treatment
for stage I seminoma presented with either a tumour size
≥4 cm (n = 38, 58.4%), or RTI (n = 42, 64.6%) or both
(n = 24, 36.9%). Thirty-nine (51.3%) of the stage I semi-
noma patients aged over 40 were treated with adjuvant
chemotherapy.
Among patients with stage II seminoma, 11 (42.3%) re-
ceived three cycles of bleomycin, etoposide and cisplatin
(BEP) and 3 (11.5%) patients four of cycles of etoposide
and cisplatin (EP). Twelve (46.2%) seminoma stage II pa-
tients had radiotherapy, 11 in combination with once cycle
of carboplatin AUC7 chemotherapy in the Swiss Group for
Clinical Cancer Research (SAKK) 01/10 study. One semi-
noma stage II patient had radiotherapy only.
Radiotherapy was applied in five (45.5%) stage IIA and
seven (70.0%) stage IIB seminoma patients.
Five (41.7%) stage III seminoma patients were treated with
three cycles BEP, five (41.7%) patients with four cycles of
EP, and one (9.1%) patient received two cycles BEP fol-
lowed by two cycles of etoposide, ifosfamide and cisplatin
(VIP) each. One patient was treated in the TIGER study
protocol after relapse [18]. One seminoma patient under-
went resection of residual disease after chemotherapy com-
pletion.
Of the stage I non-seminoma patients, 33 (57.9%) chose
active surveillance. All 30 (52.6%) patients without LVI
and thus with low-risk disease opted for active surveil-
lance. Twenty-six (45.6%) stage I non-seminoma patients
had LVI+ as high-risk feature. Only 3 (11.5%) of these
chose active surveillance, whereas 23 (88.5%) were treated
with adjuvant chemotherapy consisting of one or two cy-
cles of BEP. One (1.8%) non-seminoma stage IS patient
was treated with three cycles of BEP. In one patient with
sarcomatoid features on histology, two cycles VIP were
given as adjuvant chemotherapy, and one non-seminoma
stage I patient (1.8%) was treated with radiotherapy.
Of the stage II non-seminoma patients, 27 (93.1%) were
treated with three cycles of BEP, 2 (6.9%) with four cycles
of EP and none with radiotherapy. In stage III non-semi-
noma GCTs, 13 patients (61.9%) were treated with three
or four cycles of BEP. Four patients (19.0%) were treated
with four cycles of VIP. Two patients (9.5%) received
four cycles of EP. One (4.8%) patient was switched to the
Group d’Étude des Tumeurs Urogénitales (GETUG) 13
protocol [19] after one cycle of BEP, and one (4.8%) had
three cycles of BEP followed by one cycle of EP. Fifteen
(14.0%) patients underwent resection of residual disease
after completing chemotherapy; most were in stage III.
Summary of treatment is displayed in table 4 for semino-
mas and table 5 for non-seminoma GCTs.
Health-related and socioeconomic patient characteris-
tics
At inclusion, mean body mass index (BMI) was 25.4 (SD
3.4) and 25.5 (SD 4.1) kg/m2. Mean blood pressure was
132/81 (SD 15.7/9.9) mm Hg and 130/80 (SD 14.0/11.8)
mm Hg in seminoma and non-seminoma patients, respec-
tively.
Testosterone levels after orchiectomy, chemo- or radiother-
apy were available for only 70 (36.5%) and 33 (30.8%)
of seminoma and non-seminoma patients, respectively. Of
these, 14 (7.3%) seminoma and 6 (5.6%) non-seminoma
patients had abnormally low testosterone values (<9.72
nmol/l) with a mean value of 5.3 (SD 2.8) and 3.4 (SD 2.8)
nmol/l in seminoma and non-seminoma patients, respec-
tively. In seminoma, a total of 43 (22.4%) had semen cry-
opreservation before treatment. For 53 (49.5%) non-semi-
noma patients cryopreservation was performed.
Fifteen (7.8%) and 9 (8.4%) of seminoma and non-semi-
noma patients, respectively, had no or only compulsory ed-
ucation. One hundred and eight (56.3%) and 61 (57.0%),
respectively, had finished an apprenticeship, and 14 (7.3%)
and 11 (10.3%), respectively, high school. Fifty-two
(27.1%) seminoma and 22 (20.6%) non-seminoma patients
had a college or university degree. Most patients were em-
ployed at inclusion in SAG TCCS: 176 (91.7%) seminoma
and 93 (86.9%) non-seminoma patients.
There were 49 (25.5%) current smokers and 10 (5.2%)
current substance abusers in the seminoma population at
the time of inclusion. Among non-seminoma patients, 33
(30.8%) were current smokers and 11 (10.3%) current sub-
stance abusers.
Discussion
We report first data from SAG TCCS. This is the first tri-
national cohort study that prospectively collects data from
seminoma and non-seminoma patients after completion of
GCT treatment and from start of follow-up, thus providing
insight into baseline characteristics and patterns of care.
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Outcome data will be presented at a later time. In contrast,
many other reports on GCT baseline characteristics and
patterns of care were retrospective in nature.
One major limitation of our cohort is that all recruiting
sites are secondary or tertiary referral centres. This causes
bias and our data may not reflect routine practise and care
for GCT patients in Switzerland, Austria and Germany.
The mean age in our cohort was 40.9 years (SD 11.7) for
seminoma and 31.1 years (SD 9.3) for non-seminoma pa-
tients and compares well with other series [20, 21]. How-
ever, in a retrospective analysis from North Texas, a region
with a significant native-born and immigrant Hispanic
population, Hispanic patients presented with GCT at a sig-
nificantly younger age (mean ± SD 29.9 ± 8.9 years ) than
non-Hispanic white (NHW) patients (34.0 ± 11.2 years).
Table 1: Patient characteristics of the SAG TCCS cohort I.
Seminoma Non-seminoma p-value
n % n %
Total 192 100.0 107 100.0
Age at inclusion
Mean (SD) in years 40.9 (11.7) 31.1 (9.3) <0.001
<40 years 96 50.0 94 87.9
≥40 years 96 50.0 13 12.1 <0.001
Tumour diameter
Median (IQR) in cm 3.5 (2.5–5.0) 3.5 (2.3–4.5) 0.30
≥4 cm 81 42.2 39 36.4
<4 cm 101 52.6 59 55.1
Not available 4 2.1 5 4.7
Clinical stage
I 154 80.2 57 53.3 <0.001
II 26 13.5 29 27.1 0.47
IIA 11 5.7 13 12.1
IIB 10 5.2 14 13.1
IIC 5 2.6 2 1.9
III 12 6.3 21 19.6 0.18
Extragonadal 3 1.6 5 4.7
IGCCCG prognosis group
Good prognosis 34 17.7 39 36.4
Stage II 25 73.5† 29 74.4†
Stage III 9 26.5† 10 25.6†
Intermediate prognosis 4 2.1 6 5.6
Stage II 1 25†
Stage III 3 75† 6 100†
Poor prognosis – – 5 4.7
Stage II – –
Stage III – – 5 100†
Elevated preoperative tumour markers
AFP 8 4.2 59 55.1 <0.001
HCG 36 18.8 59 55.1 <0.001
LDH 39 20.3 28 26.2 0.25
At least one elevated tumour marker 58 30.2 78 72.9 <0.001
Stage I any marker elevation 40 (of 154) 26.0* 37 (of 57) 64.9* <0.001
Stage II any marker elevation 9 (of 26) 34.6* 22 (of 29) 75.9* 0.003
Stage III any marker elevation 8 (of 11) 72.7* 19 (of 21) 90.5* 0.31
RTI
Yes 89 46.4 64 59.8 0.005
No 86 44.8 32 29.9
Not available 17 8.9 11 10.3
LVI
Yes 45 23.4 56 52.3 <0.001
No 134 69.8 46 43.0
Not available 13 6.8 5 4.7
Histological characterisation non-seminoma
>50% seminoma – – 5 4.7
>50% embryonal carcinoma – – 50 46.7
>50% yolk sac tumour – – 7 6.5
>50% chorion carcinoma – – 3 2.8
>50% teratoma – – 7 6.5
AFP = alpha-fetoprotein; HCG = human chorionic gonadotropin; IGCCCG = International Germ Cell Cancer Collaborative Group; IQR = interquartile range; LDH = lactate dehy-
drogenase; LVI = lymphovascular infiltration; RTI = rete testis invasion; SAG TCCS = Swiss Austrian German Testicular Cancer Cohort Study; SD = standard deviation; * % of
stage † % of IGCCCG prognosis group
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This approximately 5 year age difference was seen both in
the institutional cohort and a query to the National Can-
cer Database [22]. Interestingly, in the retrospective analy-
sis from Germany, the mean age of patients with GCT in-
creased significantly from 28 years (before 1990) to 36
years (2005–2010). Likewise, age shifts were found in
both of the histological subgroups. Mean age rose from 34
to 39 years in seminoma and from 26 to 31 years in non-
seminoma patients. The aetiology of the increasing age
at diagnosis in a predominantly Caucasian population re-
mains unclear [20].
In our cohort, 192 (64.2%) seminoma patients and 107
(35.8%) non-seminoma patients were enrolled. In accor-
dance with epidemiological studies, the distribution of
seminomas and non-seminoma GCTs has been changing
over the years, and pure seminoma has become the more
common histology. Interestingly, in the stage I seminoma
and non-seminoma cohorts presented by Kollmannsberger
et al., an equal distribution between seminomas and non-
seminoma tumours was seen [6]. The SAG TCCS cohort is
similar to the East Anglian GCT group data (58% semino-
ma patients in the 1996–2002 period) [23] and Danish na-
tional data with 60% seminomas and 40% non-seminoma
tumours among all stage I GCTs [24].
In past decades there has been a significant reduction in
size of the primary tumour from 5 to 4 cm, as reported in
the East Anglian GCT group database [23]. The German
National Seminoma Registry Study (NSR study) reported
Table 2: Patient characteristics of the SAG TCCS cohort II.
Seminoma Non-seminoma p-value
n % n %
Total 192 100.0 107 100.0
Vital signs
Mean BMI (SD) in kg/m2 25.4 (3.4) 25.5 (4.1) 0.83
Mean BP (SD) in mm Hg 132/81 (15.7/9.9) 130/80 (14.0/11.8)
Tobacco use
Current 49 25.5 33 30.8 0.35
Substance abuse
Current 10 5.2 11 10.3 0.11
Education completed
None 3 1.6 3 2.8
Compulsory education 15 7.8 9 8.4
Apprenticeship 108 56.3 61 57.0
Higher education 14 7.3 11 10.3
Technical college 29 15.1 11 10.3
University/ETH 23 12.0 11 10.3
Not available 1 0.9
Employment status
Employed 176 91.7 93 86.9
Employee 150 85.2* 88 94.6*
Self employed 26 14.8* 5 5.4*
Not employed 16 8.3 14 13.1
Unemployed 4 25.0* 2 14.3*
Student 2 12.5* 11 78.6*
Homemaker 2 12.5*
Retired 4 25.0*
Unable to work 4 25.0* 1 7.1*
BMI = body mass index; BP = blood pressure; ETH = Swiss Federal Institute of Technology; SAG TCCS = Swiss Austrian German Testicular Cancer Cohort Study; SD = standard
deviation * % of total
Table 3: Patient characteristics of the SAG TCCS cohort III.
Seminoma Non-seminoma p-value
n % n %
Total 192 100.0 107 100.0
Cryopreservation
All 43 22.4 53 49.5 <0.001
≥40 5 2.6
<40 38 19.8 53 49.5 0.016
Contralateral biopsy
All 71 37.8 59 55.1 0.005
Not available 4 2.1
Postoperative testosterone
Normal (9.72–35.17 nmol/l) 56 29.2 27 25.2
Abnormal (<9.72 nmol/l) 14 7.3 6 5.6
Not available 122 63.5 74 69.2
mean (SD value) nmol/l 5.3 (2.8) 3.4 (2.8)
SAG TCCS = Swiss Austrian German Testicular Cancer Cohort Study; SD = standard deviation
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a mean tumour size in stage I seminoma of 3.67 ± 2.1 cm.
In the cohort from North Texas, testicular tumour size was
4.1 ± 2.8 cm in NHW patients compared with 5.9 ± 4.6
cm in Hispanic patients [22]. Both tumour size ≥4 cm and
RTI were present in 38 of 154 (24.6%) stage I seminoma
patients in our cohort, compared with 33% in the Spanish
Germ-Cell Cancer Group (SGCCG) cohort [25]. In stage
I seminoma, tumour size and RTI have been described as
risk factors for relapse: presence of both was associated
with a 5-year relapse rate of 32% and absence of both with
a 5-year relapse rate of 12% [26]. Later studies have not
validated both factors, and whereas previously tumour size
was used in the form of a cut-off of 4 cm, it is now also
postulated to be a continuous variable. However, in a re-
cent publication both tumour diameter >4 cm and RTI were
confirmed as independent risk factors for relapse [27]. Fur-
thermore, a systematic literature search and analysis of 19
studies proposed tumour size in stage I seminoma as the
most valuable prognostic factor [28].
LVI+ is a risk factor for relapse in non-seminoma stage I.
Twenty-six of 57 (45.6%) non-seminoma stage I patients in
SAG TCCS were LVI+, whereas in the Swedish and Nor-
wegian Testicular Cancer Group (SWENOTECA) cohort
36% were LVI+ [9].
Table 4: Summary of treatment in seminoma patients.
n %
Total 192 100.0
Stage I 154 80.2
Active surveillance 89 57.8*
Tumour diameter ≥4 cm 24 27.0†
RTI 32 36.0†
Tumour diameter ≥4 cm with RTI 14 15.7†
Tumour diameter <4 cm without RTI 42 47.2†
Age ≥40 years 37 41.6†
Carboplatin AUC7 (1 cycle) 61 39.6*
Tumour diameter ≥4cm 35 57.4†
RTI 40 65.6†
Tumour diameter ≥4 cm with RTI 23 37.7†
Tumour diameter <4 cm without RTI 9 14.8†
Age ≥40 years 37 60.7†
Carboplatin AUC7 (2 cycles, overtreatment) 3 1.9*
Tumour diameter ≥4 cm 2 66.7†
RTI 2 66.7†
Tumour diameter ≥4 cm with RTI 1 33.3†
Age ≥40 years 1 33.3†
Carboplatin AUC7 (1 cycle) and RT (overtreatment) 1 0.6*
Tumour diameter ≥4 cm 1 100.0†
Age ≥40 years 1 100.0†
Stage II 26 13.5
Good prognosis 14 53.8*
BEP (3 cycles) 11 78.6‡
EP (4 cycles) 3 21.4‡
Intermediate prognosis
Radiotherapy 12 46.2*
RT only 1 8.3†
RT and carboplatin AUC7 (1 cycle) 11 91.7†
Stage IIA 5 41.7†
Stage IIB 7 58.3†
Stage IIC
Stage III 12 6.3
Good prognosis 9 75.0*
BEP (3 cycles) 4 44.4‡
EP (4 cycles)
TIGER protocol, ASCT
4 44.4‡
1 11.2‡
Intermediate prognosis 3 25.0*
BEP (3 cycles, undertreatment) 1 33.3+
EP (4 cycles, undertreatment) 1 33.3+
BEP (4 cycles)
VIP (4 cycles)
BEP (2 cycles), VIP (2 cycles) 1 33.3‡
Resection 1 0.5
Stage II
Stage III 1 100.0†
ASCT = autologous stem cell transplantation; AUC = area under the curve; BEP = bleomycin, etoposide, cisplatin; EP = etoposide, cisplatin; RT = radiotherapy; RTI = Rete testis
invasion; TIGER protocol = 2 × paclitaxel and ifosfamide, 3 × carboplatin and etoposide; VIP = etoposide, ifosfamide, cisplatin * % of stage † % of treatment type ‡ % of prognosis
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Fifty-eight (30.2%) seminoma patients presented with
marker-positive disease before start of treatment (semicas-
tration or salvage chemotherapy after relapse), mostly as
elevated HCG (n = 36, 18.8%). In our cohort, the mark-
er-positive rate for stage I seminoma at diagnosis was a
little higher than the rate reported by Aparico et al. (26%
in SAG-TCCS vs 15%) [29]. In eight seminoma patients
(4.2%), AFP was mildly elevated. Theoretically, elevated
AFP is a sign of non-seminomatous histology, but it can
also be elevated in non-malignant conditions such as al-
cohol abuse, hepatitis, cirrhosis, biliary tract obstruction
and other conditions such as Fanconi anaemia. Some in-
dividuals have familial, hereditary, mildly elevated serum
AFP levels in the range of 15 to 30 µg/l [30]. Just recent-
ly a report on mildly elevated AFP among patients after
treatment completion in GCT, among them 4 seminoma
patients, was published. The authors postulated that mild-
ly elevated and stable AFP should be managed with sur-
veillance [31]. For seminoma patients the rate of elevated
HCG is reported at 20 to 30% in advanced disease and the
rate of increased LDH at 40 to 60% in all stages [32].
A total of 78 (72.9%) non-seminoma patients showed
marker-positive disease, which is in line with the experi-
ence of the SGCCG [25]. Our data show elevated AFP and
HCG with an equal distribution (55.1% each). Any tumour
marker was elevated in stage I, II and III in 64.5, 75.9 and
90.5% of patients, respectively. These results are compara-
ble to published data [32].
More seminoma patients were diagnosed in stage I com-
pared with non-seminoma patients (n = 154, 80.2% and
n = 57, 53.3%). Seminoma stage I represented >50% of
all GCT cases in our study; therefore recommendations for
the management of these patients are particularly impor-
tant since they affect the largest population [20].
As to treatment decisions, 42.2% of stage I seminoma pa-
tients received adjuvant chemotherapy in our cohort. In the
prospective SWENOTECA cohort of stage I seminomas,
52.3% of the patients opted for adjuvant chemotherapy,
and in the NSR study 57.8% of patients did so [21, 27].
Most recurrences on adjuvant chemotherapy occur with-
in 3 years and can effectively be treated with cisplatin-
based chemotherapy, with cure rates of 99% [6]. Adjuvant
Table 5: Summary of treatment in non-seminoma patients.
n %
Total 107 100.0
Stage I 57 53.3
Active surveillance 33 57.9*
LVI+ 3 9.1†
Age ≥40 years 2 12.1†
BEP adjuvant 22 38.6*
LVI+ 22 100.0†
Age ≥40 years 2 3.5†
1 cycle 19 86.4†
2 cycles 2 9.1†
3 cycles (overtreatment) 1 4.5†
EP adjuvant
VIP adjuvant (2 cycles, not standard treatment) 1 1.8*
LVI+ 1 100.0†
Age ≥40 years 1 100.0†
Radiotherapy (not standard treatment) 1 1.8*
Age ≥40 years 1 100.0†
Stage II 29 27.1
Good prognosis 29 100.0*
BEP (3 cycles) 27 93.1‡
EP (4 cycles) 2 6.9‡
Intermediate and poor prognosis 0 0
Stage III 21 19.6
Good prognosis 10 47.6*
BEP (3 cycles) 8 80.0‡
EP (4 cycles) 2 20.0‡
Intermediate and poor prognosis 11 52.4*
BEP (3 cycles, undertreatment) 1 9.1‡
BEP (3 cycles), EP (1 cycle) 1 9.1‡
BEP (4 cycles) 4 36.4‡
VIP (4 cycles) 4 36.4‡
BEP (1 cycle), GETUG-13 Protocol (4 cycles) 1 9.1‡
Postchemotherapy resection 15 14.0
Stage I (not standard treatment) 1 1.8*
Stage IIA 1 3.4*
Stage IIB 3 10.3*
Stage IIC 0 0
Stage III 10 47.6*
BEP = bleomycin, etoposide, cisplatin; EP = etoposide, cisplatin; GETUG = group d’étude des tumeurs urogénitales; LVI+ = lymphovascular invasion; RT = radiotherapy; VIP =
etoposide, ifosfamide, cisplatin * % of stage † % of treatment type ‡ % of prognosis group
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chemotherapy with carboplatin AUC7 yields a 75% re-
lapse risk reduction to about 4% in stage I seminoma with-
out risk adaption, hence significantly fewer men need
chemotherapy or radiotherapy for metastatic disease [33].
Recurrence after initial adjuvant treatment with carboplatin
displays the same excellent survival probability as de-novo
metastatic disease, with a 5-year overall survival of 98%
[34]. In a seminal paper, relapse-free rates for patients
treated with carboplatin AUC7 were not inferior to adju-
vant radiotherapy, but with less short-term toxicity, no sig-
nificant effect on fertility and almost no long-term toxic-
ity compared with radiation (although long term data are
sparse) [35, 36]. Therefore, radiotherapy is no longer stan-
dard of care in stage I seminoma and should be reserved
for special cases. For stage I seminoma, active surveillance
and treatment with adjuvant chemotherapy are options.
Shared decision-making with the patient about adjuvant
chemotherapy versus active surveillance after orchiectomy
should be routine today [37]. It should be taken into con-
sideration that carboplatin offers little risk for short-term
toxicity and a significant reduction of relapse risk, but at
least an 80% risk of overtreatment. There are insufficient
data on long-term toxicity. Relapse, however, necessitates
intense salvage chemotherapy with disruption of normal
life, impaired quality of life and a substantial risk of long-
term toxicity including second malignancies and cardio-
vascular disease [38]. An adverse prognostic risk factor for
GCT-specific mortality is age above 40 years, as salvage
therapy cannot be delivered to all such patients [39], thus
indicating a potential advantage of adjuvant chemotherapy
irrespective of risk factors.
Approximately 56% of high-risk and 86% of low-risk
stage I non-seminoma patients are cured after orchiectomy
alone [6]. There is a recommendation for active surveil-
lance in low-risk and one cycle of adjuvant BEP in high-
risk stage I non-seminoma GCTs [9]. Our data show a
majority of stage I non-seminoma patients with high-risk
disease (n = 22, 88%) were treated with BEP adjuvant
chemotherapy and only 3 patients (12%) preferred active
surveillance, whereas all patients with low risk disease re-
ceived active surveillance. There is no rationale for radio-
therapy in non-seminoma stage I tumours and we would
not endorse this treatment strategy.
A systematic review and meta-analysis showed that radio-
therapy and BEP or EP chemotherapy appear to be equal
options in stage IIA and IIB seminoma. However, there is a
trend in favour of chemotherapy, with a lower incidence of
side-effects and relapse rate, especially in stage IIB [40].
Five patients with stage IIA seminoma (45.5% of all stage
IIA) and seven patients with stage IIB seminoma (70% of
all stage IIB) were treated with radiotherapy in our cohort.
All patients with advanced disease received poly-
chemotherapy and 15 patients underwent resection for
residual disease.
Two IGCCCG intermediate-prognosis stage III seminoma
patients received either three cycles of BEP or four cycles
of EP instead of four cycles of BEP. This is not according
to guidelines and represents undertreatment.
One seminoma stage I patient was treated with radiothera-
py and carboplatin, one non-seminoma stage I patient had
radiotherapy, and another non-seminoma stage I patient re-
ceived two cycles VIP, all of which are not supported by
any data.
We would like to highlight the importance of evidence-
based treatment decisions in this highly curative disease.
Prognosis appears to be associated with socioeconomic
status. GCT-specific mortality was doubled among US pa-
tients diagnosed with seminoma or non-seminoma who
were >40 years of age compared with those aged <40
years. Among men with non-seminoma tumours, non-
white race and lower socioeconomic status was also asso-
ciated with increased GCT-specific mortality [39]. In our
cohort, 18 (9.4%) and 12 (11.2%) of seminoma and non-
seminoma patients, respectively, had no or only compulso-
ry education.
Data on BMI, blood pressure, and testosterone levels serve
as a baseline and will be reassessed annually during fol-
low-up.
There are data from a systemic review and meta-analysis
on an association of current, chronic, and frequent
cannabis use with the development of GCT when com-
pared with never-use of the drug. The strongest association
was found for non-seminoma GCTs. In our cohort, twice as
many non-seminoma patients as seminoma patients were
current substance abusers (10.3 vs 5.2%) [41]. In a recently
published cohort study of 49,343 Swedish males born be-
tween 1949 and 1951 who underwent extensive medical
and psychological assessment at nationwide conscription
for the compulsory Swedish military service between 1969
and 1970, no evidence of a significant relation between
lifetime “ever” cannabis use and the subsequent develop-
ment of GCT was found, but “heavy” cannabis use (>50
times in lifetime, as reported at conscription) was associ-
ated with a 2.5-fold increased hazard of subsequent GCT.
Although the Swedish study and three previous studies
[42–44] have shown a relation between frequency and du-
ration of cannabis use and the development of GCT, evi-
dence of a clear dose-response curve – a prerequisite for
establishing a persuasive argument for the causal link – is
still lacking [45].
GCTs are the only solid tumours that can be cured in
the majority of patients with metastatic disease. However,
treatment in more advanced disease (intermediate and poor
prognosis) is more intensive and cure rates are significant-
ly lower than in the good prognosis group. Active surveil-
lance is a valid strategy in stage I GCT, but early and reli-
able detection of relapse is essential. It is important to enrol
patients in prospective studies to assess not only oncolog-
ical outcome but also therapy-associated long-term toxici-
ty, and to validate the performance of follow-up schedules
and relapse screening modalities stratified by tumour enti-
ty, stage and treatment strategy.
This is the first time that the distribution of disease, de-
tailed baseline characteristics and the treatment of men
with GCT has been collected in a prospective manner in
German speaking countries (Switzerland, Austria and Ger-
many) and therefore patterns of care have been evaluated.
Results of SAG TCCS will inform on outcome, future
modifications of surveillance schedules and follow-up pro-
cedures.
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